

Professor Schmid will focus on the novel target therapies and endocrine therapies in HR+/Her2- metastatic breast cancer and how these agents will be incorporated to treatment practice in the near future. Adopting these contemporary agents may require biomarker testing and thus Professor Schmid will also share the biomarker testing practice from UK. Last but not least, he will also build on what to expect in the near future on novel combination strategies.